Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands
Michelle MA Kip, Jos A van Oers, Arezoo Shajiei, Albertus Beishuizen, AM Sofie Berghuis, Armand R Girbes, Evelien de Jong, Dylan W de Lange, Maarten WN Nijsten, Maarten J IJzerman, Hendrik Koffijberg, Ron Kusters
CRITICAL CARE | BMC | Published : 2018
BACKGROUND: Procalcitonin (PCT) testing can help in safely reducing antibiotic treatment duration in intensive care patients with sepsis. However, the cost-effectiveness of such PCT guidance is not yet known. METHODS: A trial-based analysis was performed to estimate the cost-effectiveness of PCT guidance compared with standard of care (without PCT guidance). Patient-level data were used from the SAPS trial in which 1546 patients were randomised. This trial was performed in the Netherlands, which is a country with, on average, low antibiotic use and a short duration of hospital stay. As quality of life among sepsis survivors was not measured during the SAPS, this was derived from a Dutch foll..View full abstract
DWL reports grants from Thermo Fisher during the conduct of the SAPS-trial from which data has been used for this study. All other authors declare no competing interests related to this manuscript.